Olaparib companion diagnostic - Myriad Genetics

Drug Profile

Olaparib companion diagnostic - Myriad Genetics

Alternative Names: BRACAnalysis (Olaparib); BRACAnalysis (olaparib); BRACAnalysis CDx (Olaparib); Olaparib - BRACAnalysis; Olaparib - BRACAnalysis CDx

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Myriad Genetics
  • Developer AstraZeneca; Myriad Genetics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer; Ovarian cancer
  • Phase III Pancreatic cancer
  • Clinical Phase Unknown Fallopian tube cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 06 Apr 2018 Olaparib companion diagnostic - Myriad Genetics is available for licensing in Japan as of 02 Apr 2018. www.myriad.com
  • 02 Apr 2018 Registered for Breast cancer (Diagnosis, Metastatic disease) in Japan (unspecified route)
  • 12 Jan 2018 Registered for Breast cancer (Diagnosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top